The Enterprise Value as of November 2024 (TTM) for Syros Pharmaceuticals, Inc. (SYRS) is 9.82M

According to Syros Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.82M. This represents a change of -93.33% compared to the average of 147.24M of the last 4 quarters.

Syros Pharmaceuticals, Inc. (SYRS) Historical Enterprise Value (quarterly & annually)

How has SYRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Syros Pharmaceuticals, Inc. over the last ten years is 135.27M. The current 9.82M Enterprise Value has changed 625.81% with respect to the historical average. Over the past ten years (40 quarters), SYRS's Enterprise Value was at its highest in in the December 2020 quarter at 558.20M. The Enterprise Value was at its lowest in in the September 2022 quarter at -46915075.64.

Syros Pharmaceuticals, Inc. (SYRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Syros Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Syros Pharmaceuticals, Inc. (SYRS) Average Enterprise Value

How has SYRS Enterprise Value performed in the past?

The current Enterprise Value of Syros Pharmaceuticals, Inc. (SYRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Syros Pharmaceuticals, Inc. (SYRS) Enterprise Value vs. Peers

How is SYRS’s Enterprise Value compared to its peers?

Syros Pharmaceuticals, Inc.’s Enterprise Value is greater than Surrozen, Inc. (250.67K), less than Bolt Biotherapeutics, Inc. (30.96M), less than Larimar Therapeutics, Inc. (363.34M), less than Keros Therapeutics, Inc. (1.75B), less than Kezar Life Sciences, Inc. (36.78M), less than IDEAYA Biosciences, Inc. (1.93B), less than Syndax Pharmaceuticals, Inc. (1.24B), less than Xencor, Inc. (1.81B), less than REGENXBIO Inc. (502.58M), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Black Diamond Therapeutics, Inc. (139.97M), less than Stoke Therapeutics, Inc. (457.69M), greater than Homology Medicines, Inc. (-103303255.00), less than Harpoon Therapeutics, Inc. (861.85M), less than Passage Bio, Inc. (24.72M), greater than Pasithea Therapeutics Corp. (-5435245.00), greater than Kronos Bio, Inc. (5.32M), greater than Quoin Pharmaceuticals, Ltd. (-162664.00), less than RenovoRx, Inc. (21.40M), greater than Spero Therapeutics, Inc. (-8426888.00), less than Coherus BioSciences, Inc. (259.52M), less than Gracell Biotechnologies Inc. (5.61B), greater than Neoleukin Therapeutics, Inc. (-6333315.00),

Build a custom stock screener for Syros Pharmaceuticals, Inc. (SYRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syros Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Syros Pharmaceuticals, Inc. (SYRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Syros Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.